economy
AstraZeneca should stick to its winning formula. It doesn’t need a $400bn US mega-merger
The Anglo-Swedish drugmaker’s flirtation with a grand combo with US group Bristol Myers Squibb is baffling
TL;DR
- AstraZeneca CEO Sir Pascal Soriot is reportedly considering a $400 billion merger with Bristol Myers Squibb (BMS).
- The potential deal raises concerns about financial risks, debt, and inheriting BMS's patent cliff for its Opdivo cancer treatment.
- Critics argue the merger is out of character for AstraZeneca and could jeopardize Soriot's legacy.
- AstraZeneca's existing strategy of organic growth, licensing, and partnerships, particularly in China, has been successful.
- US competition regulators might also pose challenges to the merger.
- Shareholders reacted negatively to the news, with AstraZeneca's share price falling.
- The article suggests the proposed merger should be dropped in favor of AstraZeneca's current successful strategy.